In vitro assessment, using thrombin generation, of the applicability of prothrombin complex concentrate as an antidote for Rivaroxaban

Journal of Thrombosis and Haemostasis

Volumn 11, Issue 6, 2013, Pages 1111-1118

  Dinkelaar, J ^a   Molenaar, P J ^a   Ninivaggi, M ^b   de Laat, B ^b,c   Brinkman, H J M ^d   Leyte, A ^a  

^a Onze Lieve Vrouwe Gasthuis   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d SANQUIN RESEARCH   (Netherlands)

Author keywords

Coagulation tests; Prothrombin complex concentrate; Prothrombin time; Rivaroxaban; Thrombin generation; Tissue factor

Indexed keywords

PROTHROMBIN COMPLEX; RIVAROXABAN; WARFARIN;

AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG CONCENTRATION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; NORMAL HUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTHROMBIN TIME; THROMBIN TIME; THROMBOCYTE POOR PLASMA;

COAGULATION TESTS; PROTHROMBIN COMPLEX CONCENTRATE; PROTHROMBIN TIME; RIVAROXABAN; THROMBIN GENERATION; TISSUE FACTOR;

ANTICOAGULANTS; AREA UNDER CURVE; BLOOD COAGULATION; BLOOD COAGULATION FACTORS; BLOOD COAGULATION TESTS; CALIBRATION; FIBRINOLYTIC AGENTS; HUMANS; MORPHOLINES; PLASMA; PROTHROMBIN; PROTHROMBIN TIME; THIOPHENES; THROMBIN; THROMBOPLASTIN; TIME FACTORS; VITAMIN K;

EID: 84883812030     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12236     Document Type: Article

References (23)

1. http://www.xareltohcp.com/sites/default/files/pdf/xarelto_0.pdf. Accessed 28 February 2013.
2. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Info rmation/human/000944/WC500057108.pdf. Accessed 29 April 2013.
3. Altman R, Vidal HO. Battle of oral anticoagulants in the field of atrial fibrillation scrutinized from a clinical practice (the real world) perspective. Thromb J 2011; 9: 12.
4. Bauer KA. Recent progress in anticoagulant therapy: oral direct inhibitors of thrombin and factor Xa. J Thromb Haemost 2011; 9: 12-9.
5. Romualdi E, Rancan E, Siragusa S, Ageno W. Managing bleeding complications in patients treated with the old and the new anticoagulants. Curr Pharm Des 2010; 16: 3478-82.
6. Smith SA, Morrissey JH. Polyphosphate as a general procoagulant agent. J Thromb Haemost 2008; 6: 1750-6.
7. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011; 124: 1573-9.
8. Marlu R, Hodaj E, Paris A, Albaladejo P, Crackowski JL, Pernod G. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb Haemost 2012; 108: 217-24.
9. Godier A, Miclot A, Le Bonniec B, Durand M, Fischer AM, Emmerich J, Marchand-Leroux C, Lecompte T, Samama CM. Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model. Anesthesiology 2012; 116: 94-102.
10. Molenaar PJ, Dinkelaar J, Leyte A. Measuring Rivaroxaban in a clinical laboratory setting, using common coagulation assays, Xa inhibition and thrombin generation. Clin Chem Lab Med 2012; 50: 1799-807.
11. Samama MM, Martinoli JL, Le Flem L, Guinet C, Plu-Bureau G, Depasse F, Perzborn E. Assessment of laboratory assays to measure rivaroxaban-an oral, direct factor Xa inhibitor. Thromb Haemost 2010; 103: 815-25.
12. Devreese K, Wijns W, Combes I, van kerckhoven S, Hoylaerts MF. Thrombin generation in plasma of healthy adults and children: chromogenic versus fluorogenic thrombogram analysis. Thromb Haemost 2007; 98: 600-13.
13. Ninivaggi M, Apitz-Castro R, Dargaud Y, de Laat B, Hemker HC, Lindhout T. Whole-blood thrombin generation monitored with a calibrated automated thrombogram-based assay. Clin Chem 2012; 58: 1252-9.
14. Dienava-Verdoold I, Marchetti MR, te Boome LC, Russo L, Falanga A, Koene HR, Mertens K, Brinkman HJ. Platelet-mediated proteolytic down regulation of the anticoagulant activity of protein S in individuals with haematological malignancies. Thromb Haemost 2012; 107: 468-76.
15. Nadler SB, Nadler SB, Hidalgo JU, Bloch T. Prediction of blood volume in normal human adults. Surgery 1962; 51: 224-32.
16. Parhami-Seren B, Butenas S, Krudysz-Amblo J, Mann KG. Immunologic quantitation of tissue factors. J Thromb Haemost 2006; 4: 1747-55.
17. Perzborn E, Strassburger J, Wilmen A, Pohlmann J, Roehrig S, Schlemmer KH, Straub A. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939-an oral, direct Factor Xa inhibitor. J Thromb Haemost 2005; 3: 514-21.
18. Kohler M. Thrombogenicity of prothrombin complex concentrates. Thromb Res 1999; 95: S13-7.
19. Al Dieri R, Peyvandi F, Santagostino E, Giansily M, Mannucci PM, Schved JF, Béguin S, Hemker HC. The thrombogram in rare inherited coagulation disorders: its relation to clinical bleeding. Thromb Haemost 2002; 88: 576-82.
20. Dargaud Y, Lienhart A, Negrier C. Prospective assessment of thrombin generation test for dose monitoring of bypassing therapy in hemophilia patients with inhibitors undergoing elective surgery. Blood 2010; 116: 5734-7.
21. Millet A, Graveleau J, Gueret P, Trossaërt M, Decaux O, Aouba A, Lasne D, Guillet B. Thrombin generation in patients with acquired haemophilia and clinical bleeding risk. Br J Haematol 2011; 153: 136-9.
22. Gatt A, Riddell A, Calvaruso V, Tuddenham EG, Makris M, Burroughs AK. Enhanced thrombin generation in patients with cirrhosis-induced coagulopathy. J Thromb Haemost 2010; 8: 1994-2000.
23. Coakley M, Hall JE, Evans C, Duff E, Billing V, Yang L, McPherson D, Stephens E, Macartney N, Wilkes AR, Collins PW. Assessment of thrombin generation measured before and after cardiopulmonary bypass surgery and its association with postoperative bleeding. J Thromb Haemost 2011; 9: 282-92.